Published in final edited form as:

Nature. 2000 March 30; 404(6777): 510–514. doi:10.1038/35006670.

DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation

Michael J. Difilippantonio^{*}, Jie Zhu[†], Hua Tang Chen[†], Eric Meffre[‡], Michel C. Nussenzweig[‡], Edward E. Max[§], Thomas Ried^{*}, and André Nussenzweig[†]

^{*}Genetics Department, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA

[†]Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA

[‡]Laboratory of Molecular Immunology, and Howard Hughes Medical Institute, The Rockefeller Institute, New York, New York 10021, USA

[§]Laboratory of Cell Regulation, Center for Biologics Evaluation and Research, Food and Drug Administration, National Institutes of Health, Bethesda, Maryland 20892, USA

Abstract

Cancer susceptibility genes have been classified into two groups: gatekeepers and caretakers¹. Gatekeepers are genes that control cell proliferation and death, whereas caretakers are DNA repair genes whose inactivation leads to genetic instability. Abrogation of both caretaker and gatekeeper function markedly increases cancer susceptibility. Although the importance of Ku80 in DNA double-strand break repair is well established, neither Ku80 nor other components of the non-homologous end-joining pathway are known to have a caretaker role in maintaining genomic stability. Here we show that mouse cells deficient for *Ku80* display a marked increase in chromosomal aberrations, including breakage, translocations and aneuploidy. Despite the observed chromosome instabilities, *Ku80*^{-/-} mice have only a slightly earlier onset of cancer^{2,3}. Loss of p53 synergizes with Ku80 to promote tumorigenesis such that all *Ku80*^{-/-}*p53*^{-/-} mice succumb to disseminated pro-B-cell lymphoma before three months of age. Tumours result from a specific set of chromosomal translocations and gene amplifications involving IgH and c-Myc, reminiscent of Burkitt's lymphoma. We conclude that *Ku80* is a caretaker gene that maintains the integrity of the genome by a mechanism involving the suppression of chromosomal rearrangements.

The three subunits of the DNA-dependent protein kinase, Ku70, Ku80 and DNA-PKcs, are, together with XRCC4 and Ligase IV, essential for the non-homologous end-joining (NHEJ) pathway in mammalian cells. Mice that carry the targeted disruption of components of the NHEJ pathway share some common phenotypic features including arrested lymphocyte development and increased sensitivity to ionizing radiation^{3–9}. Deficiencies in Ku80, Ku70, XRCC4 and Ligase IV, but not in DNA-PKcs, result in growth retardation and decreased

proliferation *in vitro*. This senescence has been proposed to result from an inability to repair double-strand breaks (DSBs) in DNA incurred during normal DNA metabolism³.

p53 monitors chromosome damage and either arrests cell-cycle progression or triggers apoptosis in cells with unrepaired lesions¹⁰. To determine whether p53 is involved in the growth arrest of *Ku80*^{-/-} mice and mouse embryo fibroblasts (MEFs), we generated *Ku80*^{-/-}*p53*^{-/-} double-mutant mice. The absence of *p53* did not markedly affect the initial viability of *Ku80*^{-/-}*p53*^{-/-} mice, and they were indistinguishable in size from *Ku80*^{-/-} littermates. By contrast, inactivation of *p53* did alleviate the growth arrest of the *Ku80* knock-out MEFs (Fig. 1a, b). *Ku80*^{-/-}*p53*^{-/-} cells proliferated as rapidly and saturated at a similar density as *p53*^{-/-} cells (Fig. 1a), and contained a significantly greater cycling population than *Ku80*^{-/-} MEFs (Fig. 1b). Although the *Ku80*^{-/-} proliferation defect was abrogated by the concomitant loss of *p53*, *Ku80*^{-/-}*p53*^{-/-} MEFs were more sensitive to DNA damage induced by ionizing radiation than *p53*^{-/-} or wild-type controls (Fig. 1c). After γ -irradiation, *Ku80*^{-/-}*p53*^{-/-} MEFs initially accumulated in the G2/M phase of the cell cycle (Fig. 1d). Within 48–96 hours after irradiation, *Ku80*^{-/-}*p53*^{-/-} MEFs lost their adherence to the tissue culture dish, exhibited extensive nuclear fragmentation and showed an increase in the number of cells with a DNA content less than that in G0/G1 (not shown). By contrast, *Ku80*^{-/-} MEFs were arrested permanently in the G0/G1 and G2/M phases of the cell cycle in response to γ -irradiation³ (Fig. 1d). Thus, p53 is required for early senescence in *Ku80*^{-/-} fibroblasts, indicating that cell-cycle arrest in these cells is correlated with an accumulation of DNA damage (see below). The fact that a loss of p53 does not rescue the size of *Ku80*^{-/-} mice indicates either that the dwarfism is unrelated to DNA damage or that *Ku80*^{-/-}*p53*^{-/-} cells that sustain irreparable damage are eliminated by p53-independent mechanisms *in vivo*.

Although *Ku80*^{-/-}*p53*^{-/-} mice developed normally, all ($n = 11$) such mice died within 12 weeks after birth (Fig. 2a) from disseminated lymphoma. Tumour cells expressed B-cell lineage-specific surface markers B220, CD19 and CD43, but were negative for IgM, indicating maturational arrest at the pro-B-cell stage of development (Fig. 2b; right panel, *Ku80*^{-/-}*p53*^{-/-} 8 weeks). In contrast, *p53*^{-/-} mice are predisposed to thymic lymphomas¹¹, which develop at a slower rate than *Ku80*^{-/-}*p53*^{-/-} pro-B-cell lymphomas (Fig. 2a), and *Ku80*^{-/-} mice only occasionally develop lymphoma² (only 1 out of 11 *Ku80*^{-/-} mice developed T-cell lymphoma (Thy1.2⁺, CD4⁺, CD8⁺) after seven months). We conclude that the loss of *p53* in the *Ku80* knockout background invariably results in the rapid onset of B-lineage tumours before the age at which T-lineage tumours occasionally arise in *Ku80*^{-/-} mice.

The shift from T-cell to B-cell lymphomas in *Ku80*^{-/-}*p53*^{-/-} mice was not accompanied by an obvious alteration in T- or B-lineage surface markers. *Ku80*^{-/-}*p53*^{-/-} thymocytes resembled *Ku80*^{-/-} thymocytes in that they developed no further than the CD4⁺CD8⁻ stage (Fig. 2b; left panel), whereas B cells remained arrested at the B220⁺, CD19⁺, CD43⁺, IgM⁻ pro-B-cell stage (Fig. 2b; right panel). However, the loss of *p53* had different effects on the survival of T-cell and B-cell precursors. Whereas both *Ku80*^{-/-} pro-B and pro-T cells showed high susceptibility to apoptosis (as indicated by annexin staining; data not shown) and poor proliferation, loss of *p53* from the double knockouts seemed to rescue *Ku80*^{-/-}

pro-B cells, but not pro-T cells (not shown), allowing normal proliferation *in vitro* (Fig. 2c). We conclude that p53 is required for the induction of apoptosis in B-lymphocyte but not T-lymphocyte precursors that harbour chromosome abnormalities induced by the loss of *Ku80*. This difference might in part explain the increased susceptibility of *Ku80*^{-/-}*p53*^{-/-} mice to B-lineage malignancies.

The observation that *Ku80*^{-/-}*p53*^{-/-} mice develop lymphomas at an accelerated rate suggests that Ku80 and p53 normally cooperate to limit the oncogenic potential of DSBs during assembly of the antigen receptor gene. Chromosome analysis by spectral karyotyping (SKY)¹² revealed karyotype heterogeneity within each *Ku80*^{-/-}*p53*^{-/-} tumour (*n* = 4), exemplified by translocations and apparently random gains or losses of whole chromosomes (Fig. 3a). Metaphases from 20 identically treated *Rag2*^{-/-} pro-B cells exhibited no detectable aberrations. All tumours contained a translocation of chromosome 12, on which the immunoglobulin heavy chain (IgH) is located (Fig. 3b; SKY). In three tumours (T2, T3 and T4) the partner was chromosome 15, whereas in the remaining tumour (T1) chromosome 3 was the fusion partner (Fig. 3b; SKY). The one *Ku80*^{-/-} T-cell lymphoma that arose during the 7-month observation period exhibited a translocation that fused chromosomes 3 and 7 (not shown). Thus, both *Ku80*^{-/-} and *Ku80*^{-/-}*p53*^{-/-} mice develop lymphomas that exhibit chromosome translocations.

Translocations between chromosomes 12 and 15 in *Ku80*^{-/-}*p53*^{-/-} lymphomas resemble the translocations in mouse plasmacytomas and Burkitt's lymphomas that juxtapose the *c-myc* oncogene to the IgH locus¹³. Translocations involving the IgH locus, but not *c-myc*, have been reported in B-cell lymphomas arising from crosses between *SCID* (severe combined immunodeficiency) mice—which are defective in DNA-PKcs—and *p53*^{-/-} mice¹⁴. We therefore performed fluorescence *in situ* hybridization (FISH) analysis to determine whether *c-myc* and IgH genes were translocated in *Ku80*^{-/-}*p53*^{-/-} lymphomas. All *Ku80*^{-/-}*p53*^{-/-} lymphomas showed co-localization of *c-myc* and IgH with an apparent amplification of both genes (Fig. 3b; IgH, *c-myc*). In the one *Ku80*^{-/-}*p53*^{-/-} tumour that showed a 12:3 translocation, *c-myc* and IgH co-localized precisely at the breakpoint between chromosomes 12 and 3, indicating a three-way (12:15:3) translocation (Fig. 3c). Amplification of *c-myc* and IgH was confirmed by Southern blot analysis (Fig. 3d), and IgH locus rearrangements were found in all tumours (Fig. 3d). Furthermore, FISH analysis mapped the breakpoint on chromosome 12 to between the IgH variable cluster and constant region (Fig. 3b; IgH V, IgH C). We conclude that *Ku80*^{-/-}*p53*^{-/-} lymphomas result from a specific set of chromosomal translocations and amplifications involving *c-myc* and IgH, and therefore differ from *SCIDxp53*^{-/-} B-cell lymphomas¹⁴. DNA-PKcs-independent functions of Ku, as established in previous studies, might contribute to the cytogenetic differences in these tumours^{3,15}.

To determine the precise nature of the translocations in *Ku80*^{-/-}*p53*^{-/-} lymphomas, we cloned the novel JH-hybridizing *Eco*RI fragment from one of the four tumours (Fig. 3d; T2). Sequence analysis revealed that the 2.5-kilobase (kb) fragment was a fusion of JH1 to a 173-base pair (bp) segment that bore no significant homologies to previously reported sequences. To determine the chromosomal origin of the 173-bp DNA fragment, FACS-sorted chromosomes were screened by PCR (Fig. 3e). Unfractionated liver DNA and purified

chromosome 15 DNA showed a signal, whereas chromosomes 2, 9 and 12 were negative (Fig. 3e). Loss of the variable region on the der(12) chromosome and the proximity of the translocation to JH1 suggest that the translocation resulted from aberrant repair of DNA breaks produced in pro-B cells during V(D)J recombination.

One of the hallmarks of malignant transformation is genomic instability, which promotes a wide range of mutations, including chromosome deletions, gene amplifications, translocations and polyploidy¹⁶. To determine whether loss of *Ku80* results in chromosome instability, we karyotyped metaphases from passage-1 MEFs (Fig. 4). Whereas only 9% of metaphases from wild-type mice were karyotypically abnormal, we observed profound aberrations in the integrity of the *Ku80*^{-/-} genome (Fig. 4a); 83% of *Ku80*^{-/-} metaphases had breaks or translocations (Fig. 4a) and 15% displayed polyploidy (that is, $3n$, $4n$ or $5n$ chromosome content, where $2n$ reflects a normal diploid complement). Although chromosome aberrations have been reported in primary dermal fibroblasts from *Ku80*^{-/-}, *Ku80*^{+/-} and ligase IV^{+/-} mice¹⁷, we found no significant differences between *Ku80*^{+/-} and wild-type MEFs. The pattern of damage in the *Ku80*^{-/-} metaphases was further characterized by SKY, which showed chromatid breaks, acentric fragments, triradials, dicentrics, duplications and asymmetric exchanges (Fig. 4b). *Ku80*^{-/-}*p53*^{-/-} MEFs were similar to *Ku80*^{-/-}, whereas *p53*^{-/-} MEFs had slightly fewer aberrations (Fig. 4a). Thus, the absence of Ku80 precipitates genomic instability, which is not augmented by the additional loss of p53.

An apparently random gain or loss of chromosomes also occurred in 70% of *Ku80*^{-/-} MEFs (not shown). Because aneuploidy has been associated with centrosome amplification in *BRCA1*^{-/-} and *p53*^{-/-} MEFs^{18,19}, we looked at these structures in early-passage MEFs. Our analysis of γ -tubulin structures revealed a similar centrosome amplification in both *Ku80*^{-/-}*p53*^{-/-} and *p53*^{-/-} MEFs. However, despite the numerical aberrations seen in *Ku80*^{-/-} MEFs, centrosomes in these cells were indistinguishable from normal fibroblast controls (Fig. 4c; not shown). Thus, the acquisition of numerical chromosome aberrations in *Ku80*^{-/-} MEFs occurs by a mechanism unrelated to centrosome amplification.

Unresolved signal ends in *Ku80*^{-/-} lymphocytes might contribute to the development of translocations by acting as transposable elements^{20,21}. Alternatively, gross chromosomal rearrangements in *Ku80*^{-/-} mice might result from the absence of Ku-mediated tethering of broken ends, which normally facilitates their subsequent ligation^{22,23}. Promiscuous chromosome fusions in the absence of Ku80 could either be accomplished by other components of the apparatus of the NHEJ pathway (that is, Ku70, DNA-PKcs, XRCC4 or Ligase IV) or involve alternative DNA repair pathways such as single-strand annealing or break-induced replication²⁴. In either case, the finding that Ku80 suppresses gross genomic rearrangements places Ku80 in the class of caretaker genes, which include *ATM*, *BRCA1* and several proteins that function in homologous recombination^{1,25,26}. p53 provides an additional safeguard against the genomic instability inherent in Ku80-deficient cells by either arresting cell division (as in *Ku80*^{-/-} MEFs) or triggering apoptosis (as in *Ku80*^{-/-} B lymphocytes). Consistent with this model is the observation that the abrogation of both Ku80 caretaker and p53 gatekeeper functions markedly increases malignant transformation, especially in lymphocytes that undergo physiological DSBs during the course of V(D)J

recombination. Whereas the phenotype of *Ku80*^{-/-} mice is more severe than that of *DNA-PKcs*^{-/-} mice, we would expect that other components of the NHEJ machinery (Ku70, XRCC4 and Ligase IV) also have an essential role in maintaining genomic stability. Thus, mutation of the NHEJ pathway components might facilitate the development of malignancy by increasing the frequency of chromosomal aberrations.

Methods

Generation and screening of mice

Ku80 mutant mice were generated from *Ku80*^{+/-} intercrosses and screened by polymerase chain reaction (PCR) as described³. *p53*^{-/-} mice were obtained from Taconic Laboratories, and *p53* genotyping was performed as described^{27,28}. Mice heterozygous for *Ku80* and *p53* were crossed to obtain progeny homozygous for both *Ku80*-null and *p53*-null alleles. To generate mouse embryo fibroblasts, *Ku80*^{+/-}*p53*^{-/-} males were crossed with *Ku80*^{+/-}*p53*^{+/-} females and embryos were isolated 13.5 days after plug formation³.

Growth and irradiation assays

Passage-1 MEFs (10⁵) were plated in duplicate six-well dishes and the medium was replaced daily. Individual dishes were treated with trypsin, counted and averaged. For continuous labelling experiments, 10⁵ cells were plated with 50 µM bromodeoxyuridine (BrdU) and grown for 16 h. Cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibodies and propidium iodide (PI) in accordance with the manufacturer's specifications (Becton Dickinson). For radiation survival experiments, cells were exposed to graded doses of γ-rays, counted 4 d after irradiation, and normalized to the number of cells in unirradiated controls of the same genotype. Aliquots fixed at 24–96 h after irradiation were stained with PI for measurements of DNA content.

Spectral karyotyping, FISH and immunocytochemistry

MEFs from wild-type, *p53*^{-/-}, *Ku80*^{-/-} and *Ku80*^{-/-}*p53*^{-/-} mice were cultured in DMEM containing 10% fetal bovine serum (FBS). Suspensions of tumour cells derived from lymph node were grown in RPMI containing 10% FBS, 50 units ml⁻¹ interleukin-7 (IL-7) (R&D Systems) and 20 units ml⁻¹ IL-2 (Boehringer Mannheim). Tumour T1 was analysed after one passage in culture, whereas T2, T3 and T4 were primary tumours that were processed immediately for SKY, FISH and Southern blot analysis. MEFs and tumour cells were arrested at mitosis by treatment with Colcemid (Gibco/BRL) at 0.1 µg ml⁻¹ for 0.5–3 h. Mitotic chromosome spreads were prepared by following standard procedures, and SKY analysis was performed as described¹². For FISH analysis, metaphases were hybridized with BAC probes for the following regions: IgH constant region from C_{γ1} to 3' of C_α, IgH variable region representing the distal end of the V cluster (VJ588), and *c-myc*. Flow-sorted single chromosomes were used for painting probes. Immunostaining of centrosomes with γ-tubulin antibodies was performed as described²⁹.

Flow cytometry

Single-cell suspensions from thymocytes, bone marrow, lymph node and tumours were stained for various lineage-specific surface markers as described³. The following

monoclonal antibodies (PharMingen) were used in various two-colour combinations: phycoerythrin (PE)-conjugated anti-CD4 (clone RM4-5), FITC-conjugated anti-CD8a (clone 53-6.7), FITC-conjugated anti-T-cell antigen receptor (clone H57-597), PE-conjugated anti-B220 (clone RA3-6B2), FITC-conjugated anti-CD19 (clone 1D3), FITC-conjugated anti-IgM (clone II/41), FITC-conjugated anti-CD43 (clone S7) and PE-conjugated Thy1.2 (clone 53-2.1). At least 100,000 data points were collected on a modified immunocytometry systems FACSSTAR Plus using CellQuest software (Becton Dickinson).

Lymphocyte purification and culture

Bone marrow B cells from mutant and wild-type mice were enriched by positive selection with MACS mouse CD19 microbeads (Miltenyi Biotech). Wild-type B cells were further sorted into B220⁺CD43⁺CD25⁻IgM⁻ pro-B cells. Pro-B cells were co-cultured for 3 d with irradiated S17 stromal cells and mouse rIL-7 (10 ng ml⁻¹). Wild-type CD4⁻CD8⁻ T-cell precursors were enriched by negative selection with magnetic beads coated with anti-mouse CD4 and anti-mouse CD8 (Dynal). Apoptosis and viability of B and T cells were analysed with PE-Annexin (PharMingen) and staining with PI.

Southern blot analysis and digestion–circularization PCR

Genomic DNA (10 µg) from *Ku80*^{-/-}*p53*^{-/-} tumours was digested with *Eco*RI. Southern blots were sequentially hybridized to ³²P-labelled probes for *c-myc* and mouse actin cDNA; a duplicate blot was prepared and sequentially hybridized with a 1.1-kb JH4 and a 900-bp Cµ genomic fragment. For digestion–circularization PCR³⁰, 2 µg of genomic DNA was digested with *Eco*RI and ligated under dilute conditions that promote self-ligation³⁰. Primers JH4F (5'-CTTCCCCAAATAGCCTTGCC-3') and JH4R (5'-CCCACCAAACCG AAAGTCCA-3') were used to amplify the 2.5-kb product by using the Expand High Fidelity PCR System (Boehringer). The amplified product was cloned into PCR-XL-TOPO (Invitrogen) and individual clones were isolated for sequencing. PCR primers PTK2F (5'-TGAGTTTCTTGGGTGTGGGC-3') and PTK2R (5'-GCATAGGATTC GGCGTAGA-3'), derived from the 173-bp sequence fused to JH1, were used to screen 10 ng of DNA derived from liver and flow-sorted mouse chromosomes 2, 9, 12 and 15.

Acknowledgments

We thank A. Singer, R. Hodes, A. Bhandoola, E. Besmer and S. Sharrow for comments on the manuscript and helpful discussions; K. Huppi, B. Malynn and R. Riblet for probes; and D. Liewehr, S. Steinberg and T. Brotz for assistance. M.C.N. is an investigator of the Howard Hughes Medical Institute. A.N. was supported in part by an award from the Arthritis Foundation.

References

1. Kinzler KW, Vogelstein B. Gatekeepers and caretakers. *Nature*. 1997; 386:761–763. [PubMed: 9126728]
2. Vogel H, Lim DS, Karsenty G, Finegold M, Hasty P. Deletion of Ku86 causes early onset of senescence in mice. *Proc. Natl Acad. Sci. USA*. 1999; 96:10770–10775. [PubMed: 10485901]
3. Nussenzweig A, et al. Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. *Nature*. 1996; 382:551–555. [PubMed: 8700231]

4. Zhu C, Bogue MA, Lim DS, Hasty P, Roth DB. Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates. *Cell*. 1996; 86:379–389. [PubMed: 8756720]
5. Ouyang H, et al. Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination *in vivo*. *J. Exp. Med.* 1997; 186:921–929. [PubMed: 9294146]
6. Gu Y, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. *Immunity*. 1997; 7:367–376.
7. Gao Y, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. *Cell*. 1998; 95:891–902. [PubMed: 9875844]
8. Frank KM, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. *Nature*. 1998; 396:173–177. [PubMed: 9823897]
9. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. *Curr. Biol.* 1998; 8:1395–1398. [PubMed: 9889105]
10. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell*. 1997; 88:323–331. [PubMed: 9039259]
11. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. *Curr. Biol.* 1994; 4:1–7. [PubMed: 7922305]
12. Liyanage M, et al. Multicolour spectral karyotyping of mouse chromosomes. *Nature Genet.* 1996; 14:312–315. [PubMed: 8896561]
13. Taub R, et al. Translocation of the *c-myc* gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc. Natl Acad. Sci. USA*. 1982; 79:7837–7841. [PubMed: 6818551]
14. Vanasse GJ, et al. Genetic pathway to recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase. *J. Clin. Invest.* 1999; 103:1669–1675. [PubMed: 10377173]
15. Gao Y, et al. A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. *Immunity*. 1998; 9:367–376. [PubMed: 9768756]
16. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature*. 1998; 396:643–649. [PubMed: 9872311]
17. Karanjawala ZE, Grawunder U, Hsieh CL, Lieber MR. The nonhomologous DNA end joining pathway is important for chromosome stability in primary fibroblasts. *Curr. Biol.* 1999; 9:1501–1504. [PubMed: 10607596]
18. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. *Science*. 1996; 271:1744–1747. [PubMed: 8596939]
19. Xu X, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. *Mol. Cell.* 1999; 3:389–395. [PubMed: 10198641]
20. Agrawal A, Eastman QM, Schatz DG. Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. *Nature*. 1998; 394:744–751. [PubMed: 9723614]
21. Hiom K, Melek M, Gellert M. DNA transposition by the Rag1 and Rag2 proteins: a possible source of oncogenic translocations. *Cell*. 1998; 94:463–470. [PubMed: 9727489]
22. Ramsden DA, Gellert M. Ku protein stimulates DNA end joining by mammalian DNA ligases: a direct role for Ku in repair of DNA double-strand breaks. *EMBO J.* 1998; 17:609–614. [PubMed: 9430651]
23. Smith GCM, Jackson SP. The DNA-dependent protein kinase. *Genes Dev.* 1999; 13:916–934. [PubMed: 10215620]
24. Chen C, Umezu K, Kolodner RD. Chromosomal rearrangements occur in *S. cerevisiae* rfa1 mutator mutants due to mutagenic lesions processed by double-strand-break repair. *Mol. Cell.* 1998; 2:9–22. [PubMed: 9702187]
25. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. *Mol. Cell.* 1999; 4:511–518. [PubMed: 10549283]

26. Johnson RD, Liu N, Jasin M. Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. *Nature*. 1999; 401:397–399. [PubMed: 10517641]
27. Timme TL, Thompson TC. Rapid allelotyping analysis of p53 knockout mice. *Biotechniques*. 1994; 17:462–463.
28. Donehower LA, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature*. 1992; 356:215–221. [PubMed: 1552940]
29. Ghadimi BM, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. *Genes Chromosomes Cancer*. 2000; 27:183–190. [PubMed: 10612807]
30. Chu CC, Paul WE, Max EE. Quantitation of immunoglobulin μ - γ 1 heavy chain switch region recombination by a digestion–circularization polymerase chain reaction method. *Proc. Natl Acad. Sci. USA*. 1992; 89:6978–6982. [PubMed: 1495989]

Figure 1.

Growth characteristics of untreated and irradiated mouse embryo fibroblasts. **a**, Growth kinetics of $Ku80^{-/-}$ (open circles), $p53^{-/-}$ (filled triangles), $Ku80^{-/-}p53^{-/-}$ (filled circles) and wild-type (filled squares) MEFs. **b**, Incorporation of BrdU in MEF cultures after 16 h of continuous labelling. **c**, Radiation sensitivity of $Ku80^{-/-}p53^{-/-}$ (circles), $p53^{-/-}$ (triangles) and wild-type (squares) MEFs, plotted as the fraction of surviving cells relative to unirradiated samples of the same genotype. $Ku80^{-/-}$ MEFs exhibited a sevenfold decrease in cell count independent of the dose (83–600 cGy) owing to the premature senescence of

unirradiated cultures, and the permanent arrest of the dividing population in response to γ -irradiation. **d**, DNA content histogram measured in untreated samples (control) and in cultures 24 h after treatment with 10 Gy of γ -radiation (Irradiated).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 2.

Analysis of lifespan and lymphocyte development. **a**, Kaplan–Meier analysis comparing mortality of $Ku80^{+/+}p53^{-/-}$ (triangles) and $Ku80^{-/-}p53^{-/-}$ (circles) mice as a function of time. The survival of $Ku80^{-/-}p53^{-/-}$ mice is statistically different from that of the $Ku80^{+/+}p53^{-/-}$ group; $P = 0.0001$. **b**, Flow cytometric analysis of thymocyte (left panel) and bone-marrow (right panels) suspensions obtained from wild-type, $Ku80^{-/-}$ and $Ku80^{-/-}p53^{-/-}$ mice. An 8-week-old $Ku80^{-/-}p53^{-/-}$ mouse, which had a B-cell lymphoma, is compared with a 4-week-old non-tumour-bearing $Ku80^{-/-}p53^{-/-}$ mouse, and with 4-

week-old $Ku80^{-/-}$ and wild-type littermates. Data are representative of 10 wild-type, 6 $Ku80^{-/-}$, 5 non-tumour-bearing $Ku80^{-/-}p53^{-/-}$ mice 2–4 weeks old, and 12 $Ku80^{-/-}p53^{-/-}$ animals that had tumours. Average thymus cellularity was 5×10^5 in $Ku80^{-/-}$ mice, 10^6 in non-tumour-bearing $Ku80^{-/-}p53^{-/-}$ mice and 2×10^8 in wild-type controls. Average number of B220⁺CD19⁺ cells in bone marrow was 4.6×10^5 in $Ku80^{-/-}$ mice, 9.6×10^5 in non-tumour-bearing $Ku80^{-/-}p53^{-/-}$ mice and 2.8×10^6 for wild-type controls. The immunophenotypes of $Ku80^{+/+}p53^{-/-}$ and wild-type mice were similar (not shown). **c.** Survival of wild-type (WT) B220⁺CD43⁺IgM[−] pro-B cells, and $Ku80^{-/-}p53^{-/-}$ and $Ku80^{-/-}$ CD19⁺ B cells after 1 d (open columns) and 3 d (filled columns) in culture, plotted relative to input cell number at day 0. Results from two independent $Ku80^{-/-}p53^{-/-}$ mice are plotted.

Figure 3. *c-myc* and IgH-associated rearrangements and amplifications in *Ku80*^{-/-}*p53*^{-/-} tumours. **a**, Average number of translocations (other than those juxtaposing chromosomes 12 and 15), unshaded, or gains and losses of chromosomes, shaded, in *Ku80*^{-/-}*p53*^{-/-} tumours (T1–T4). **b**, SKY analysis revealed translocations involving chromosomes (Chr.) 12 (pink) and 15 (blue) in *Ku80*^{-/-}*p53*^{-/-} tumours 2–4 (T2–T4) and 12 and 3 (green) in T1. FISH with probes for IgH C_{γ1-α} (red) and *c-myc* (green) reveal co-localization and co-amplification of these genes as well as signals on the normal chromosomes. Analysis with probes for IgH variable (orange) and constant (green) regions show co-localization on the normal chromosome 12. The absence of the variable region on the derivative 12 shows that this translocation disrupts the IgH locus. Chromosomes in the middle and right panels were identified by hybridization

with painting probes (as in **c**) and are counterstained with 4,6-diamidino-2-phenylindole (DAPI; blue). **c**, Five-colour FISH analysis of a metaphase from tumour T1. The inset shows the localization of individual *c-myc* and IgH signals at the breakpoint between chromosomes 12 and 3. **d**, Southern blot analysis showing germline bands (stars) as well as rearrangements (arrows) and/or amplifications of *c-myc* and IgH. **e**, PCR amplification of tumour 2 breakpoint indicates that the JH1 fusion partner originated from chromosome 15. Abbreviations: C: Liver; T1–T4: *Ku80*^{−/−}*p53*^{−/−} tumors 1–4.

Figure 4. Chromosome aberrations in *Ku80*^{-/-} and *Ku80*^{-/-}*p53*^{-/-} MEFs. **a**, Percentage of cells with DNA breaks or translocations, shaded ($n = 35$), and polyploidy, unshaded ($n = 400$), observed in passage 1 MEFs. WT, wild type. **b**, Typical chromosome aberrations found in *Ku80*^{-/-} MEFs. From left to right, chromatid break, acentric fragment, tri-radial, dicentric, duplication and an asymmetric exchange. **c**, γ -Tubulin staining for centrosomes (green) in *Ku80*^{-/-} (left) and *Ku80*^{-/-}*p53*^{-/-} (right) MEFs counterstained with propidium iodide (red).